Telomir Pharmaceuticals (Telomir Pharmaceuticals) ROCE % : -237.50% (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Telomir Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Telomir Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2024 was -237.50%.

Telomir Pharmaceuticals ROCE % Historical Data

The historical data trend for Telomir Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telomir Pharmaceuticals ROCE % Chart

Telomir Pharmaceuticals Annual Data

Trend

Dec21

Dec22

Dec23

ROCE %

-913.95

Telomir Pharmaceuticals Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial				-	-146.67	-125.80	-1,220.09	-237.50

Telomir Pharmaceuticals ROCE % Calculation

Telomir Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-11.429	/	( ( (0.049 - 0.986)	+	(4.774 - 1.336) )	/ 2 )
	=	-11.429	/	( (-0.937	+	3.438)	/ 2 )
	=	-11.429	/	1.2505
	=	-913.95 %

Telomir Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-7.664	/	( ( (4.774 - 1.336)	+	(3.503 - 0.487) )	/ 2 )
	=	-7.664	/	( ( 3.438	+	3.016 )	/ 2 )
	=	-7.664	/	3.227
	=	-237.50 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Telomir Pharmaceuticals (NAS:TELO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Telomir Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Telomir Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telomir Pharmaceuticals Inc (NAS:TELO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Telomir Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells.

Telomir Pharmaceuticals (Telomir Pharmaceuticals) Headlines

From GuruFocus

UPDATE -- Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

By GlobeNewswire • 03-29-2024